PathAI

PathAI is a digital pathology platform using AI to assist in or replace histopathology slide reading in oncology. Its flagship product, AISight Dx, covers breast, lung, and head-and-neck tumors with FDA 510(k) clearance (primary diagnosis US) and CE-IVD marking (primary diagnosis EU, UK, Switzerland). PathAI has raised roughly $240 million and ranks among the best-capitalized health AI startups. In 2023-2025, Quest Diagnostics acquired PathAI's CLIA lab and licensed the AISight platform, broadening access via one of the US's largest pathology networks.

PathAI does not officially offer a French-language interface. Pricing is entirely custom quotes based on lab size, annual slide volume, and required AI modules. Typical costs include annual license, cloud infrastructure (AWS/Azure), and specialized algorithms. An API enables integration to the lab's LIS. The main challenge for a small European structure is the need to digitize slides (expensive hardware, €100k-500k) before AI can engage. The absence of formalized local regulatory approval in Europe (CE-IVD applies EU-wide but does not ensure national clearance) may complicate deployment under strict regulatory frameworks.